Table 1 summarizes RG7204 molecular weight our hospital’s mean variable costs for each procedure. Indirect costs, such as lost earnings due to poor health, were not estimated. In Italy the cost of each sorafenib capsule is around €50. Because not all patients are able to receive the whole

therapeutic dose (four capsules/day), from the proportion of patients receiving more than 80% of the planned daily dose in the Sharp trial11 we calculated a median three capsules for each day of treatment, for each patient treated both on the WL and in BCLC stage C (after removal from the WL). For HCC patients removed from the WL due to tumor progression (patients with BCLC stages B and C), we also considered a minimum follow-up cost for palliative care. Sorafenib therapy and its related costs have been accepted in Italy on the strength of the results of the Sharp trial.11 In a Markov model specifically designed to calculate WTP, we therefore included the results of the Sharp trial and the cost per capsule accepted by the Italian public health system (Table 1). Considering a median 5 months of time on the treatment,11 and a median number of three capsules/day,11 we calculated a median overall cost of the sorafenib therapy per patient at Abiraterone molecular weight €22,500. From the median survival times for the

sorafenib and placebo groups in the Sharp trial (10.7 and 7.9 months, respectively), and using the pre-LT quality of life utility for HCC patients,21 we calculated a crude utility of sorafenib therapy of 65 QALDs, so the calculated WTP was €346 per extra day of life. Patients were followed up for 10 years in the model, including periods before and after transplantation. The length of the Markov cycle was 1 day, and survival was adjusted for quality of life, based on specific utilities. Annual and monthly probabilities

were converted into daily probabilities using a linear decay function.15 Quality of life was determined for pre- and posttransplant patients by means of a systematic review of the literature, as described elsewhere.16, 17 We assumed the same utility for all HCC patients before LT whatever their tumor stage. Quality-adjusted life expectancy was discounted at a rate of 3% a year. All analyses were performed using the TreAge Prov2009 (TreAge Software, Williamstown, MA). A Monte this website Carlo probabilistic sensitivity analysis was used to understand the impact of variable uncertainties on the model results and to estimate the confidence that can be placed in analyzing such results. We assumed that the distribution of each variable included in our model followed a beta distribution. Moreover, we set the number of distribution samples of the Monte Carlo simulation at 1,000. For descriptive purposes, we performed conventional one- and two-way sensitivity analyses to show the correlation between the study endpoints and specific crucial variables (sorafenib HR and median time to LT).